Home › Funds › State Street › State Street SPDR S&P Pharmaceuticals ETF
Fund family: State Street · Filed by SPDR SERIES TRUST (CIK 1064642) · SEC series S000012321
Ticker: XPH (C000033537)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 272 with, 211 against, 0 abstentions (not counted as with management). Shareholder proposals: 0 FOR, 9 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as State Street’s manager page (773,265 ballot items across 134 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | State Street | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 92.1% | 456 | 89.7% | 592,191 |
| Backed environmental and social shareholder proposals at US companies | n/a | 4 | 6.8% | 3,767 |
Each ballot item this fund voted is set against the votes of the other State Street funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted the same way as most State Street funds on all 453 items where a comparison was possible.
The same votes as “with management” above, by the sector of the company voted on. 95.7% of this fund’s 483 such votes could be given a sector; the other 21 (4.3%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 451 | 200 | 44.3% |
| Industrials | 11 | 3 | 27.3% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 310 | 130 |
| Audit-related | 60 | 32 |
| Say-on-Pay | 59 | 31 |
| Compensation | 22 | 12 |
| Corporate Governance | 17 | 1 |
| Capital Structure | 12 | 2 |
| Extraordinary Transactions | 4 | 0 |
| Shareholder Rights and Defenses | 3 | 1 |
| Environment or Climate | 2 | 2 |
| Other Social Issues | 2 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Xeris Biopharma Holdings, Inc. | June 4, 2026 | $17M | 4 | 2 |
| Corcept Therapeutics Incorporated | May 21, 2026 | $12M | 11 | 6 |
| Organon & Co. | June 9, 2026 | $12M | 13 | 12 |
| Viatris Inc. | May 15, 2026 | $11M | 15 | 8 |
| Amneal Pharmaceuticals, Inc. | May 6, 2026 | $11M | 12 | 11 |
| MBX Biosciences, Inc. | June 4, 2026 | $11M | 3 | 0 |
| Amylyx Pharmaceuticals, Inc. | June 4, 2026 | $10M | 4 | 3 |
| Pacira Biosciences, Inc. | June 9, 2026 | $9M | 10 | 6 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| June 4, 2026 | Xeris Biopharma Holdings, Inc. | To elect two Class II directors to our board of directors to serve until the 2029 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: John Johnson | For | Against |
| June 4, 2026 | Xeris Biopharma Holdings, Inc. | To approve, on a non-binding advisory basis, the compensation of our named executive officers. | For | Against |
| May 21, 2026 | Corcept Therapeutics Incorporated | Election of Directors: Gregg Alton | For | Against |
| May 21, 2026 | Corcept Therapeutics Incorporated | Election of Directors: Joseph K. Belanoff, M.D. | For | Against |
| June 9, 2026 | Organon & Co. | Election of Directors: Carrie S. Cox | For | Against |
| June 9, 2026 | Organon & Co. | Election of Directors: Robert Essner | For | Against |
| May 15, 2026 | Viatris Inc. | Election of 13 director nominees, each to hold office until the 2027 annual meeting of shareholders: W. Don Cornwell | For | Against |
| May 15, 2026 | Viatris Inc. | Election of 13 director nominees, each to hold office until the 2027 annual meeting of shareholders: JoEllen Lyons Dillon | For | Against |
| May 6, 2026 | Amneal Pharmaceuticals, Inc. | Election of Directors: Deb Autor | For | Against |
| May 6, 2026 | Amneal Pharmaceuticals, Inc. | Election of Directors: J. Kevin Buchi | For | Against |
| June 4, 2026 | Amylyx Pharmaceuticals, Inc. | Election of Directors: To elect the following persons to our board of directors, each to serve as a Class II director until the 2029 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: George Mclean Milne Jr., Ph.D. | For | Against |
| June 4, 2026 | Amylyx Pharmaceuticals, Inc. | Election of Directors: To elect the following persons to our board of directors, each to serve as a Class II director until the 2029 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Paul Fonteyne | For | Against |
Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.
491 ballot items at 62 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, State Street SPDR S&P Pharmaceuticals ETF (XPH) voted at 62 shareholder meetings of 59 companies, on 491 ballot items in all. Where management made a recommendation, the fund followed it on 56.3% of the items and voted against it 211 times. Its most frequent area of disagreement was director elections (130 of its votes against management). It voted on 12 shareholder proposals. It voted FOR the board's own proposals more often than State Street's funds as a whole (92.1% against 89.7%). It voted the same way as most State Street funds on every item where a comparison was possible. 1 of its meetings was contested.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of State Street’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.